Developing targeted therapies for kidney diseases
Nanoparticle-targeted therapeutic development for glomerular diseases
This study is working on new ways to help treat kidney diseases by using tiny particles to deliver medicine directly to the kidneys, especially for patients with chronic or severe kidney issues, and it aims to help those who are most affected, like many in the African American community.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | City College of New York NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11176072 on NIH RePORTER |
What this research studies
This research focuses on creating innovative therapies specifically designed to treat glomerular diseases, which are conditions affecting the kidney's filtering units. The project involves a collaborative team of experts in biomedical engineering, cell biology, nephrology, and pharmacology. By utilizing biocompatible nanoparticles, the research aims to enhance the delivery of therapeutic agents directly to the kidneys, potentially improving treatment outcomes for patients with chronic kidney disease and end-stage kidney disease. The approach is designed to address significant health disparities, particularly among African American populations who are disproportionately affected by these conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with chronic kidney disease or end-stage kidney disease, particularly those from African American communities.
Not a fit: Patients with kidney diseases not related to glomerular damage or those who are not eligible for new therapeutic interventions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for kidney diseases, reducing the need for dialysis and transplants.
How similar studies have performed: Previous research has shown promise in using targeted nanoparticle therapies for various conditions, suggesting potential success for this novel approach in kidney disease treatment.
Where this research is happening
New York, United States
- City College of New York — New York, United States (Active)
Researchers
- Principal investigator: Williams, Ryan Martin — City College of New York
- Study coordinator: Williams, Ryan Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.